FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379662015> ?p ?o ?g. }

• W4379662015 endingPage "15" @default.
• W4379662015 startingPage "1" @default.
• W4379662015 abstract "Although extensive research has been conducted on the role of local immunity in patients with SARS-CoV-2, little is known about the production and concentrations of secretory IgA (SIgA) in different mucosal compartments. This article aims to assess the secretion of SIgA in the nasal and pharyngeal compartments and saliva of patients with COVID-19 and to investigate the possibility and efficiency of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms.This study included 78 inpatients, aged between 18 and 60 years, who had confirmed COVID-19 with moderate lung involvement. The control group (n=45) received basic therapy, and the treatment group (n=33) was additionally administered the bacteria-based pharmaceutical Immunovac VP4 from day 1 to day 10 of hospitalization. SIgA levels were measured by ELISA at baseline and on days 14 and 30.No systemic or local reactions associated with Immunovac VP4 were reported. We observed a statistically significant reduction in the duration of fever and hospitalization in patients who received Immunovac VP4 compared with those from the control group (p=0.03 and p=0.05, respectively). Changes over time in SIgA levels in nasal swabs were found to be significantly different in the two treatment groups (F=7.9, p[78.0]<0.001). On day 14 of observation, patients in the control group showed a statistically significant reduction in SIgA levels from baseline (p=0.02), whereas patients in the Immunovac VP4 group had stable SIgA levels (p=0.07). On day 30 after the start of treatment, there was a statistically significant increase in SIgA levels in the Immunovac VP4 group compared with baseline (from 77.7 (40.5-98.7) μg/L to 113.4 (39.8-156.7) μg/L; p=0.05) and the levels measured on day 14 (from 60.2 (23.3-102.9) μg/L to 113.4 (39.8-156.7) μg/L; p=0.03). The control group showed a statistically significant decrease in levels of nasal SIgA (to 37.3) on day 30 (p=0.007 for comparison with baseline values and p=0.04 for comparison with levels measured on day 14). Changes over time in SIgA levels measured in pharyngeal swabs were also different between the two treatment groups, and this difference reached statistical significance (F=6.5, p[73.0]=0.003). In the control group, this parameter did not change throughout the study (p=0.17 for a comparison between the levels measured on day 14 and the baseline values, and p=0.12 for a comparison between the levels measured on day 30 and the baseline values). In the Immunovac VP4 group, there was a statistically significant increase from baseline in SIgA levels on study day 30: from 1.5 (0.2-16.5) μg/L to 29.8 (3.6-106.8) μg/L (p=0.02). Changes over time in salivary SIgA did not show a significant difference between study groups (F=0.3, p[66.3]=0.75).As part of combination therapy, the bacteria-based immunostimulant agent Immunovac VP4 increases SIgA levels in the nasal and pharyngeal compartments and induces clinical improvement. Induced mucosal immunity is central to the prevention of respiratory infections, particularly in patients with post-COVID-19 syndrome." @default.
• W4379662015 created "2023-06-08" @default.
• W4379662015 creator A5000545987 @default.
• W4379662015 creator A5017397910 @default.
• W4379662015 creator A5019424530 @default.
• W4379662015 creator A5021351453 @default.
• W4379662015 creator A5021542525 @default.
• W4379662015 creator A5032386698 @default.
• W4379662015 creator A5043202626 @default.
• W4379662015 creator A5046721616 @default.
• W4379662015 creator A5060460078 @default.
• W4379662015 creator A5061488168 @default.
• W4379662015 creator A5061879756 @default.
• W4379662015 creator A5064148369 @default.
• W4379662015 creator A5064524279 @default.
• W4379662015 creator A5079713372 @default.
• W4379662015 date "2023-06-12" @default.
• W4379662015 modified "2023-10-16" @default.
• W4379662015 title "Changes in nasal, pharyngeal and salivary secretory IgA levels in patients with COVID-19 and the possibility of correction of their secretion using combined intranasal and oral administration of a pharmaceutical containing antigens of opportunistic microorganisms" @default.
• W4379662015 cites W1974260720 @default.
• W4379662015 cites W1974928907 @default.
• W4379662015 cites W1987993161 @default.
• W4379662015 cites W2024919877 @default.
• W4379662015 cites W2052160940 @default.
• W4379662015 cites W2060565977 @default.
• W4379662015 cites W2060723289 @default.
• W4379662015 cites W2063036448 @default.
• W4379662015 cites W2065458595 @default.
• W4379662015 cites W2083460804 @default.
• W4379662015 cites W2094834014 @default.
• W4379662015 cites W2098311489 @default.
• W4379662015 cites W2105688062 @default.
• W4379662015 cites W2155197667 @default.
• W4379662015 cites W2163412067 @default.
• W4379662015 cites W2409245655 @default.
• W4379662015 cites W2517451726 @default.
• W4379662015 cites W2999589805 @default.
• W4379662015 cites W3012756997 @default.
• W4379662015 cites W3013893137 @default.
• W4379662015 cites W3016437870 @default.
• W4379662015 cites W3024144282 @default.
• W4379662015 cites W3026545200 @default.
• W4379662015 cites W3031259506 @default.
• W4379662015 cites W3035676609 @default.
• W4379662015 cites W3045734160 @default.
• W4379662015 cites W3045933491 @default.
• W4379662015 cites W3080374910 @default.
• W4379662015 cites W3081741393 @default.
• W4379662015 cites W3081832835 @default.
• W4379662015 cites W3081974864 @default.
• W4379662015 cites W3085197221 @default.
• W4379662015 cites W3096816634 @default.
• W4379662015 cites W3109360305 @default.
• W4379662015 cites W3125216673 @default.
• W4379662015 cites W3127594202 @default.
• W4379662015 cites W3198962373 @default.
• W4379662015 cites W4206043660 @default.
• W4379662015 cites W4225577030 @default.
• W4379662015 cites W9163700 @default.
• W4379662015 doi "https://doi.org/10.7573/dic.2022-10-4" @default.
• W4379662015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37342460" @default.
• W4379662015 hasPublicationYear "2023" @default.
• W4379662015 type Work @default.
• W4379662015 citedByCount "0" @default.
• W4379662015 crossrefType "journal-article" @default.
• W4379662015 hasAuthorship W4379662015A5000545987 @default.
• W4379662015 hasAuthorship W4379662015A5017397910 @default.
• W4379662015 hasAuthorship W4379662015A5019424530 @default.
• W4379662015 hasAuthorship W4379662015A5021351453 @default.
• W4379662015 hasAuthorship W4379662015A5021542525 @default.
• W4379662015 hasAuthorship W4379662015A5032386698 @default.
• W4379662015 hasAuthorship W4379662015A5043202626 @default.
• W4379662015 hasAuthorship W4379662015A5046721616 @default.
• W4379662015 hasAuthorship W4379662015A5060460078 @default.
• W4379662015 hasAuthorship W4379662015A5061488168 @default.
• W4379662015 hasAuthorship W4379662015A5061879756 @default.
• W4379662015 hasAuthorship W4379662015A5064148369 @default.
• W4379662015 hasAuthorship W4379662015A5064524279 @default.
• W4379662015 hasAuthorship W4379662015A5079713372 @default.
• W4379662015 hasBestOaLocation W43796620151 @default.
• W4379662015 hasConcept C126322002 @default.
• W4379662015 hasConcept C203014093 @default.
• W4379662015 hasConcept C2779134260 @default.
• W4379662015 hasConcept C2909735910 @default.
• W4379662015 hasConcept C3008058167 @default.
• W4379662015 hasConcept C49039625 @default.
• W4379662015 hasConcept C504460877 @default.
• W4379662015 hasConcept C524204448 @default.
• W4379662015 hasConcept C59377437 @default.
• W4379662015 hasConcept C71924100 @default.
• W4379662015 hasConcept C85663871 @default.
• W4379662015 hasConcept C8891405 @default.
• W4379662015 hasConcept C90924648 @default.
• W4379662015 hasConceptScore W4379662015C126322002 @default.
• W4379662015 hasConceptScore W4379662015C203014093 @default.
• W4379662015 hasConceptScore W4379662015C2779134260 @default.
• W4379662015 hasConceptScore W4379662015C2909735910 @default.
• W4379662015 hasConceptScore W4379662015C3008058167 @default.

• next